• A phase 3 trial examining Novo Nordisk's (NVO) GLP-1 medicine semaglutide as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) met its primary endpoints.
• Those endpoints were significant improvement in liver fibrosis with no worsening of steatohepatitis, and no worsening of liver fibrosis in those with MASH compared to placebo.
• In the study, 2.4 mg semaglutide was given subcutaneously once a week.
• Results from part 1 of the ESSENCE trial showed that at week 72, 62.9% of people treated with semaglutide achieved resolution of steatohepatitis with no worsening of liver fibrosis compared to 34.1% on placebo. Also, 37% of people treated with semaglutide 2.4 mg achieved improvements in liver fibrosis with no worsening of steatohepatitis compared to 22.5% on placebo.
• A secondary endpoint found 32.8% of those on semaglutide 2.4 mg achieved both resolution of steatohepatitis with improvements in liver fibrosis vs. 16.2% of placebo patients.
• Semaglutide is also sold by Novo as a type 2 diabetes medicine under the name Ozempic and as a weight loss treatment called Wegovy.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。